Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas

Journal of Clinical Oncology

Volumn 24, Issue 22, 2006, Pages 3664-3671

  Hernández, Silvia ^a   López Knowles, Elena ^a   Lloreta, Josep ^a   Kogevinas, Manolis ^a   Amorós, Alex ^a   Tardón, Adonina ^a   Carrato, Alfredo ^a   Serra, Consol ^a   Malats, Núria ^a   Real, Francisco X ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; ALANINE; CYSTEINE; FGFR3 PROTEIN, HUMAN; GLUTAMIC ACID; GLYCINE; LEUCINE; PHENYLALANINE; SERINE; TYROSINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MEDICAL RECORD; OUTCOME ASSESSMENT; PATHOLOGIST; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; UROGENITAL TRACT CANCER; BLADDER TUMOR; DNA SEQUENCE; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PREDICTION AND FORECASTING;

ADULT; AGED; AGED, 80 AND OVER; ALANINE; CYSTEINE; FEMALE; GLUTAMIC ACID; GLYCINE; HUMANS; LEUCINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHENYLALANINE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SEQUENCE ANALYSIS, DNA; SERINE; TYROSINE; URINARY BLADDER NEOPLASMS;

EID: 33747079040     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.1771     Document Type: Article

References (34)

1. Borden LS, Clark PE, Hall MC: Bladder cancer. Curr Opin Oncol 16:257-262, 2004
2. Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27:361-373, 2006
3. Wu XR: Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5:713-725, 2005
4. Rosin MP, Cairns P, Epstein JI, et al: Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 55:5213-5216, 1995
5. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264, 1994
6. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784-788, 1994
7. Hartmann A, Schlake G, Zaak D, et al: Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62:809-818, 2002
8. Cappellen D, De Oliveira C, Ricol D, et al: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20, 1999
9. Billerey C, Chopin D, Aubriot-Lorton MH, et al: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955-1959, 2001
10. Powers CJ, McLeskey SW, Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165-197, 2000
11. Ornitz DM, Marie PJ: FGF signalling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16:1446-1465, 2002
12. Horton WA, Lunstrum GP: Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. Rev Endocr Metab Disord 3:381-385, 2002
13. Vajo Z, Francomano CA, Wilkin DJ: The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 21:23-39, 2000
14. Naski MC, Wang Q, Xu J, et al: Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13:233-237, 1996
15. Sibley K, Stern P, Knowles MA: Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 20:4416-4418, 2001
16. Karoui M, Hofmann-Radvanyi H, Zimmermann U, et al: No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 20:5059-5061, 2001
17. van Rhijn BW, Lukin I, Radvanyi F, et al: The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61:1265-1268, 2001
18. van Rhijn BW, Vis AN, van der Kwast TH, et al: Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21:1912-1921, 2003
19. Bakkar AA, Wallerand H, Radvanyi F, et al: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108-8112, 2003
20. van Rhijn BW, van der Kwast TH, Vis AN, et al: FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64:1911-1914, 2004
21. Hernandez S, Lopez-Knowles E, Lloreta J, et al: FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 11:5444-5450, 2005
22. Malats N, Bustos A, Nascimento CM, et al: P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6:678-686, 2005
23. Kyzas PA, Loizou KT, Ioannidis JP: Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97:1043-1055, 2005
24. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2:416-422, 2005
25. Epstein JI, Amin MB, Reuter VR, et al: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder: Bladder Consensus Conference Committee. Am J Surg Pathol 22:1435-1448, 1998
26. Mostofi FK, Davies CJ, Sesterhenn IA Histological Typing of Urinary Blader Tumours: WHO International Histological Classification of Tumours. Berlin, Germany, Springer-Verlag, 1999
27. Eble JN, Sauter G, Epstein JI, et al: (eds): Tumours of the Urinary System and Male Genital Organs: Pathology and Genetics. WHO Classification of Tumours. Lyon, France, IARC Press, 2004
28. Armitage P, Berry G, Matthews JNS Statistical methods in medical research (ed 4). Oxford, England, Blackwell, 2002
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34:187-220, 1972
31. García-Closas M, Malats N, Silverman D, et al: Polymorphisms in N-acetyltransferase (NAT) and glutathione S-transferase (GST) genes and bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 365:649-659, 2005
32. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer Incidence, Mortality, and Prevalence Worldwide. IARC Cancerbase No. 5 version 2.0, Lyon, France, IARCPress, 2004
33. Tolley HD, Manton KG, Bumgarner JR: Risk factors affecting multiple-disease efficacy and effectiveness of interventions programs, in Dietz K, Gail M, Krickeberg K, et al, (eds): Springer Series in Statistics, Statistics in the Health Sciences, Forecasting the Health of Elderly Populations. New York, NY, Springer-Verlag, 1993
34. Malats N, Kogevinas M, Amorós A, et al: Prognostic value of p53 in bladder cancer: Results a prospective multicentric study in Spain. Proc Am Assoc Cancer Res 47, 2006 (abstr 1216)